Latest news with #GilBlum
Yahoo
26-06-2025
- Automotive
- Yahoo
Needham Reiterates a Buy Rating on Autolus Therapeutics (AUTL), Keeps the PT at $10
Autolus Therapeutics plc (NASDAQ:AUTL) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. Analyst Gil Blum from Needham reiterated a Buy rating on Autolus Therapeutics plc (NASDAQ:AUTL) on June 12, keeping the price target at $10.00. The analyst cited the promising results of the FELIX study for obe-cel in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) as one of the factors supporting the optimistic rating, stating that the updated analysis highlights a notable number of patients in remission with no need for further therapy. This is a positive indicator, according to the analyst, especially in comparison to other treatments such as Tecartus. A laboratory technician carefully studying a microscope with a biopharmaceutical product inside. While the analyst acknowledged that 38% of responders were still in remission with a median follow-up of 33 months, a slight drop from the 40% reported at 21.5 months, he stated that the results are still impressive. He also cited other promising factors, including the overall survival and event-free survival rates, as well as the absence of new safety concerns. According to Blum, these factors suggest a positive reception from physicians and the potential for higher commercial adoption of obe-cel, supporting the optimistic outlook for Autolus Therapeutics plc (NASDAQ:AUTL). Autolus Therapeutics (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company based in the United Kingdom. It develops programmed T cell therapies for treating autoimmune diseases and cancer, with a focus on chimeric antigen receptor (CAR) T cell therapy. The company engineers controlled, targeted, and highly active T cell therapy product candidates designed to recognize target cells, break their defense mechanisms down, and eliminate them. It is doing so using a portfolio of proprietary and modular T-cell programming technologies. While we acknowledge the potential of AUTL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
24-06-2025
- Automotive
- Yahoo
Needham Reiterates a Buy Rating on Autolus Therapeutics (AUTL), Keeps the PT at $10
Autolus Therapeutics plc (NASDAQ:AUTL) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. Analyst Gil Blum from Needham reiterated a Buy rating on Autolus Therapeutics plc (NASDAQ:AUTL) on June 12, keeping the price target at $10.00. The analyst cited the promising results of the FELIX study for obe-cel in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) as one of the factors supporting the optimistic rating, stating that the updated analysis highlights a notable number of patients in remission with no need for further therapy. This is a positive indicator, according to the analyst, especially in comparison to other treatments such as Tecartus. A laboratory technician carefully studying a microscope with a biopharmaceutical product inside. While the analyst acknowledged that 38% of responders were still in remission with a median follow-up of 33 months, a slight drop from the 40% reported at 21.5 months, he stated that the results are still impressive. He also cited other promising factors, including the overall survival and event-free survival rates, as well as the absence of new safety concerns. According to Blum, these factors suggest a positive reception from physicians and the potential for higher commercial adoption of obe-cel, supporting the optimistic outlook for Autolus Therapeutics plc (NASDAQ:AUTL). Autolus Therapeutics (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company based in the United Kingdom. It develops programmed T cell therapies for treating autoimmune diseases and cancer, with a focus on chimeric antigen receptor (CAR) T cell therapy. The company engineers controlled, targeted, and highly active T cell therapy product candidates designed to recognize target cells, break their defense mechanisms down, and eliminate them. It is doing so using a portfolio of proprietary and modular T-cell programming technologies. While we acknowledge the potential of AUTL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
21-05-2025
- Business
- Yahoo
Crispr Therapeutics call volume above normal and directionally bullish
Bullish option flow detected in Crispr Therapeutics (CRSP) with 2,899 calls trading, 1.4x expected, and implied vol increasing almost 2 points to 61.27%. Jun-25 30 calls and Oct-25 40 calls are the most active options, with total volume in those strikes near 910 contracts. The Put/Call Ratio is 0.14. Earnings are expected on August 5th. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on CRSP: Disclaimer & DisclosureReport an Issue Strategic Growth and De-risking: Gil Blum's Buy Rating on Crispr Therapeutics AG Promising Potential of Crispr Therapeutics AG: Buy Rating Backed by Strategic Partnership and Diversified Pipeline Crispr Therapeutics AG: Strategic Advancements and Growth Potential Drive Buy Rating Buy Rating for CRISPR Therapeutics: Strategic Collaboration with Sirius Therapeutics to Enhance Pipeline and Capture Anticoagulant Market Share Strategic Expansion and Promising Ventures Drive Buy Rating for Crispr Therapeutics AG
Globe and Mail
11-04-2025
- Business
- Globe and Mail
This Nvidia-Backed AI Stock Is Shrugging Off Market Pain Thanks to the FDA. Should You Buy Shares Now?
Recursion Pharmaceuticals (RXRX) shares closed up 27% after the Food and Drug Administration (FDA) said it wants to phase out animal testing in drug development. The U.S. regulatory authority wants to switch to 'more effective, human-relevant methods' instead, including machine learning and artificial intelligence, according to its press release on Friday. FDA's announcement is driving RXRX higher as it aligns perfectly with Recursion Pharmaceuticals' core business. The biotechnology company specializes in using AI for accelerated drug discovery. Despite today's surge, however, Recursion Pharmaceuticals stock is down nearly 55% versus its year-to-date high. Is It Too Late to Invest in Recursion Pharmaceuticals? FDA's announcement could help Recursion Pharmaceuticals push further to the upside as it has a massive dataset of more than 60 petabytes, which is one of the largest in the biotech space. Recursion already counts notable names like Roche (RHHBY), Merck (MRK), and Sanofi (SNY) as partners. And with FDA promoting the use of AI models in drug development, it's reasonable to believe that other drugmakers would want to follow suit, potentially helping RXRX shares extend gains through the remainder of 2025. In fact, the biotech stock could climb all the way back to $11 by the end of this year, according to Gil Blum – a senior analyst at Needham. Why Is Needham Bullish on RXRX Shares? Recursion Pharmaceuticals came in shy of Street estimates in its latest reported quarter in February. Still, Blum expects RXRX to nearly double from current levels as it has a promising pipeline. It's REC-617, for example, has shown encouraging results in early clinical studies. Recursion stock will extend gains as the biotechnology company continues to advance its clinical programs and capitalize on strategic partnerships to foster innovation in 2025, he added. Needham expects Recursion to achieve significant synergies from its $688 million Exscientia deal as well. What's the Consensus Rating on Recursion Stock? Other Wall Street analysts are not as bullish on Recursion Pharmaceuticals as Needham, given the consensus rating on RXRX currently sits at 'Hold.' However, their mean target of $8.50 still represents potential upside of more than 50% from here.
